Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR-E2: Vicriviroc plus optimized PI-containing ART in treatment-experienced HIV (mixed R5/X4 tropism)
2005-001058-26Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Vicriviroc arm with Placebo arm (2 arms). Primary endpoints: Antiviral efficacy at Week 24 and Time to virologic failure. Started Oct 2005; status: terminated.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-001058-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001058-26.